These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 10641592)
1. Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties. Klein BK; Olins PO; Bauer SC; Caparon MH; Easton AM; Braford SR; Abrams MA; Klover JA; Paik K; Thomas JW; Hood WF; Shieh JJ; Polazzi JO; Donnelly AM; Zeng DL; Welply JK; McKearn JP Exp Hematol; 1999 Dec; 27(12):1746-56. PubMed ID: 10641592 [TBL] [Abstract][Full Text] [Related]
2. Receptor binding kinetics of human IL-3 variants with altered proliferative activity. Klein BK; Shieh JJ; Grabbe E; Li X; Welply JK; McKearn JP Biochem Biophys Res Commun; 2001 Nov; 288(5):1244-9. PubMed ID: 11700046 [TBL] [Abstract][Full Text] [Related]
3. Saturation mutagenesis of human interleukin-3. Olins PO; Bauer SC; Braford-Goldberg S; Sterbenz K; Polazzi JO; Caparon MH; Klein BK; Easton AM; Paik K; Klover JA J Biol Chem; 1995 Oct; 270(40):23754-60. PubMed ID: 7559548 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis. Lokker NA; Movva NR; Strittmatter U; Fagg B; Zenke G J Biol Chem; 1991 Jun; 266(16):10624-31. PubMed ID: 2037601 [TBL] [Abstract][Full Text] [Related]
5. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Thomas JW; Baum CM; Hood WF; Klein B; Monahan JB; Paik K; Staten N; Abrams M; McKearn JP Proc Natl Acad Sci U S A; 1995 Apr; 92(9):3779-83. PubMed ID: 7537376 [TBL] [Abstract][Full Text] [Related]
6. A human interleukin 3 analog with increased biological and binding activities. Lopez AF; Shannon MF; Barry S; Phillips JA; Cambareri B; Dottore M; Simmons P; Vadas MA Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11842-6. PubMed ID: 1465408 [TBL] [Abstract][Full Text] [Related]
7. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313 [TBL] [Abstract][Full Text] [Related]
12. Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. Feng Y; Klein BK; McWherter CA J Mol Biol; 1996 Jun; 259(3):524-41. PubMed ID: 8676386 [TBL] [Abstract][Full Text] [Related]
13. Multisite mutagenesis of interleukin 5 differentiates sites for receptor recognition and receptor activation. Plugariu CG; Wu SJ; Zhang W; Chaiken I Biochemistry; 2000 Dec; 39(48):14939-49. PubMed ID: 11101310 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Lemoli RM; Fogli M; Fortuna A; Motta MR; Rizzi S; Benini C; Tura S Exp Hematol; 1993 Dec; 21(13):1668-72. PubMed ID: 7694867 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of neurokinin A(4-10) at the human tachykinin NK(2) receptor: the effect of amino acid substitutions on receptor affinity and function. Warner FJ; Miller RC; Burcher E Biochem Pharmacol; 2002 Jun; 63(12):2181-6. PubMed ID: 12110377 [TBL] [Abstract][Full Text] [Related]
16. Structure-function relationships of interleukin-3. An analysis based on the function and binding characteristics of a series of interspecies chimera of gibbon and murine interleukin-3. Kaushansky K; Shoemaker SG; Broudy VC; Lin NL; Matous JV; Alderman EM; Aghajanian JD; Szklut PJ; VanDyke RE; Pearce MK J Clin Invest; 1992 Nov; 90(5):1879-88. PubMed ID: 1385477 [TBL] [Abstract][Full Text] [Related]
17. Preparation of a recombinant chimaera of insulin-like growth factor II and interleukin 3 with high proliferative potency for haemopoietic cells. Difalco MR; Congote LF Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):407-13. PubMed ID: 9291112 [TBL] [Abstract][Full Text] [Related]
18. Phage presentation and affinity selection of a deletion mutant of human interleukin-3. Merlin S; Rowold E; Abegg A; Berglund C; Klover J; Staten N; McKearn JP; Lee SC Appl Biochem Biotechnol; 1997 Sep; 67(3):199-214. PubMed ID: 9332969 [TBL] [Abstract][Full Text] [Related]
19. Cytokine receptor repertoire and cytokine responsiveness of Ho(dull)/Rh(dull) stem cells with differing potentials for G1/S phase progression. Reddy GP; McAuliffe CI; Pang L; Quesenberry PJ; Bertoncello I Exp Hematol; 2002 Jul; 30(7):792-800. PubMed ID: 12135678 [TBL] [Abstract][Full Text] [Related]
20. Global Analysis of Multi-Mutants to Improve Protein Function. Johansson KE; Lindorff-Larsen K; Winther JR J Mol Biol; 2023 Apr; 435(8):168034. PubMed ID: 36863661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]